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Abstract Despite aggressive immunosuppressivetherapy,
pediatric orthotopic heart transplant (OHT) candidates with
elevated pre-transplant panel reactive antibody (PRA)
carry an increased risk of rejection and early graft failure
following transplantation. This study has aimed to more
speciﬁcally evaluate the outcomes of transplant candidates
stratiﬁed by PRA values. Records of pediatric patients
listed for OHT between April 2004 and July 2008 were
reviewed (n=101). Survival analysis was performed
comparing patients with PRA\25 to those with
PRA[25, as well as patients with PRA\80 and
PRA[80. Patients with PRA[25 had decreased survival
compared with those with PRA\25 after listing
(P = 0.004). There was an even greater difference in sur-
vival between patients with PRA[80 and those with
PRA\80 (P = 0.002). Similar analyses for the patients
who underwent successful transplantation showed no sig-
niﬁcant difference in post-transplant survival between
patients with a pre-transplant PRA[25 and those with
PRA\25 (P = 0.23). A difference approaching signiﬁ-
cance was noted for patients with PRA[80 compared
with PRA\80 (P = 0.066). Patients with signiﬁcantly
elevated pre-transplant PRAs at the time of listing have a
signiﬁcantly worse outcome compared to those with
moderately increased PRA values or non-sensitized
patients. Further study is necessary to guide physician and
family treatment decisions at the time of listing.
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Introduction
Allosensitization in pediatric OHT candidates presents a
signiﬁcant challenge for long-term survival. Sensitization
in the pediatric population most often occurs after blood
transfusion and homograft placement during surgical
repairs of congenital heart defects [7, 12]. Sensitization to
HLA antigens is augmented after ventricular assist—
device placement and after heart transplantation [8].
Although early survival may be comparable, sensitized
pediatric transplant patients have been shown to have
decreased long-term survival compared with nonsensitized
patients [4]. Furthermore, sensitized transplant recipients
are at risk for antibody mediated rejection (AMR) of the
transplanted heart [7]. AMR is considered a signiﬁcant
cause of biopsy negative, hemodynamically signiﬁcant
rejection episodes and graft failure [1, 6, 9].
Sensitization is often deﬁned as a panel reactive anti-
body (PRA) measurement[10% for either class I or II
HLA antigens [3–5, 10, 13]. A study of United Network
for Organ Sharing data in adults showed signiﬁcant
decreases in 3 year graft survival with each 20% interval
increase in pretransplant PRA value [11]. However, the
effect of increased PRA values has yet to be as speciﬁ-
cally described for the pediatric population. Our institu-
tion has historically been aggressive in attempts to
successfully transplant pediatric patients with signiﬁcantly
increased PRA levels. We describe wait list survival and
long-term graft outcomes in a pediatric population strat-
iﬁed by speciﬁc PRA levels (PRA\25, [25, \80,
and [80).
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Patients
After receiving Institutional Review Board approval,
records of all pediatric patients listed for orthotopic heart
transplantation (OHT) between April 2004 and July 2008
were reviewed. Detailed medical histories, including age at
transplant, sex, diagnosis, wait time, and cause of death,
were recorded. PRA results nearest to listing and trans-
plantation were recorded as were posttransplant endo-
myocardial biopsy (EMB) results. Patients removed from
the wait list due to recovery were excluded.
Immunosuppression
Sensitized transplant candidates routinely underwent
desensitization procedures consisting of 5 day courses of
plasmapheresis (size permitting) followed by intrave-
nous immune globulin (Baxter International, Deerﬁeld, IL).
Rituximab (Genentech, Basal, Switzerland) was also used
in select cases. Since 1995, all recipients were managed
on triple-drug immunosuppression consisting of cor-
ticosteroids, tacrolimus (Astellas Pharma, Japan), and
mycophenolate mofetil (Roche, Basel, Switzerland). Cor-
ticosteroids were ideally weaned off by 1 year after
transplantation based on favorable EMB results and stable
clinical course. Tacrolimus was replaced with Sirolimus
(Wyeth Pharmaceuticals, Collegeville, PA) in patients with
evidence of cardiac allograft vasculopathy (CAV) either
by coronary angiography or echocardiography. Recipients
with chronic renal insufﬁciency were maintained on a
renal-sparing protocol using Sirolimus in combination with
mycophenolate. Symptomatic patients with evidence of
AMR were treated with courses of plasmapheresis and
intravenous immune globulin.
Panel Reactive Antibody
During the study period, all transplant candidates were
screened for anti-HLA antibodies using ﬂow cytometry
and microlymphocytoxicity assays. Antibody reactivity in
the cytotoxicity assays was measured on a T-lymphocyte
panel consisting of 120 reference cells and a B-lym-
phocyte panel consisting of 60 reference cells. Sample
results reﬂecting [10% reactivity were retested with
dithiothreitol to remove immunoglobulin M antibodies.
Repeat assays were performed every 4–6 months while
the patient was awaiting transplantation. Repeat assays
were also performed 2 weeks after blood transfusion or
infection.
Donor-Speciﬁc Cross-Matching
Prospective cross-matches were performed in candidates
with increased PRA levels ([10%). After 2007, virtual
cross-matching largely replaced prospective donor-speciﬁc
cross-matches. Recipient sera were cross-matched directly
with donor T and B lymphocytes using the standard
microlymphocytotoxicity technique and the three color-
ﬂow cross-match technique. Sera used in the cytotoxicity
cross-match were pretreated with dithiothreitol.
EMBs
Surveillance EMBs were performed at weeks 1, 3, 12, 26,
and 52 during the ﬁrst year after transplantation. EMBs
were performed every 6 months in the second year and
then annually thereafter. Additional biopsy procedures were
performed in patients with clinical evidence of rejection or
after documented cellular rejection of grade 2R (previously
1B) or greater. Recipients presenting with hemodynamic
instability were generally treated empirically for rejection
without EMB. EMBs were subsequently performed after
bolus immunotherapy. Biopsy procedures performed at
1 week, 6 months, and yearly after OHT were screened by
immunoﬂuorescence and immunohistochemistry for AMR.
EMB specimens from symptomatic patients with suspected
AMR based on clinical presentation were also screened for
AMR. If AMR was identiﬁed, immunoﬂuorescence was
performed on all subsequent EMB specimens until a nega-
tive result was obtained. EMB specimens were analyzed as
previously described.
Statistical Analysis
Survival analysis was performed using Kaplan–Meier
curves, which were compared using Breslow test for
equality (SPSS version 8.0 for Windows; Chicago, IL). Chi
square test (SPSS version 8.0 for Windows) was used to
analyze noncontinuous variables, and two-tailed Student
t test (Excel; Microsoft, Redmond, WA) was used to ana-
lyze continuous variables, and P\0.05 were considered
signiﬁcant.
Results
Patient Demographics
A total of 101 patients listed for OHT between April 2004
and July 2008 were included in this study. Eighty-three
patients received transplants, and 18 died while on the wait.
One patient was excluded because a pretransplant PRA
could not be located, and another was excluded because
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123more than one transplant was performed during the study
period. Patients removed from the wait list due to recovery
were also excluded. The mean age at transplantation was
11.3 years (range 0.4–20.8) (Table 1). Mean wait list time
for patients who were transplanted was 75.8 days (range
1 day–1.3 years), and mean wait list time was 188.1 days
(range 12 days–4 years) for patients who did not receive
transplants (P = 0.002). There were no signiﬁcant differ-
ences in wait list time, age at transplantation, or sex for
patients with PRA[25 and PRA\25 or for patients with
PRA[80 and PRA\80 (Tables 1, 2). As expected, a
signiﬁcantly greater number of patients with congenital
heart disease (CHD) had extremely high PRA values
compared with patients with cardiomyopathies. Graft fail-
ure occurred in 19.3% of patients who received transplants
in this cohort. Two year posttransplant follow-up was
available for 56 patients.
Outcomes After Listing for OHT
A total of 81 patients (80%) had PRA\25 at listing. Wait-
list survival for patients with PRA\25 was signiﬁcantly
better than for those with PRA[25 (Fig. 1; P = 0.004).
Patients with PRA[25 did not have signiﬁcantly
longer wait times (P = 0.40). Ninety patients (89.1%) had
PRA\80 at listing and showed signiﬁcantly better sur-
vival (P = 0.002) than patients with PRA[80 (Fig. 2).
During the study period, the mortality for all patients in
this cohort, regardless of whether or not they received a
transplant, was 33.7% (n = 34). Eighteen of the patients
who died were still on the wait list at the time of death.
Twenty-eight percent of patients who died while on the
wait list had PRA[80 at listing. These patients had a
mean survival of 146 days (range 12–261) after listing. Of
the patients who died after OHT, 19% had PRA[80.
Mean survival for these patients was 2.1 years (58 days–
3.86 years) after OHT. Eleven percent of patients at listing
had PRA[80, and 7% of patients who underwent OHT
had PRA[80.
Table 1 PRA stratiﬁcation of transplanted patients by PRA at listing
PRA (n) % Female
sex (n)
P % CHD Dx (n) P Mean age
at OHT (y)
P Mean waitlist
time (d)
P % Graft failure
after 2 years (n = 56)
P
\25 (71) 35 (25) 0.90 25 (18) 0.56 11.1 0.91 77.5 0.95 19 (9/47) 0.83
[25 (12) 33 (4) 33 (4) 11.4 76.0 22 (2/9)
\80 (77) 36 (28) 0.33 26 (20) 0.69 12.7 0.83 76.21 0.93 18 (9/51) 0.23
[80 (6) 17 (1) 33 (2) 10.0 76.0 40 (2/5)
CHD congenital heart disease
Table 2 PRA stratiﬁcation of all patients listed for OHT
PRA (n) % Female
sex (n)
P % CHD
Dx
P Mean age
at listing (y)
P Mean waitlist
time (d)
P
\25 (81) 37 (30) 0.51 32 (26) 0.06 11.0 0.92 93.7 0.40
[25 (20) 45 (9) 55 (11) 11.2 125
\80 (90) 39 (35) 0.87 33 (30) 0.05 11.1 0.66 99.5 0.82
[80 (11) 36 (4) 63 (7) 9.7 108
CHD congenital heart disease
Fig. 1 Survival after listing for patients with PRA[25 and
PRA\25
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There was not a signiﬁcant difference in the absolute
2 year survival after OHT for patients with PRA\25
compared with those with PRA[25. Although it trended
toward signiﬁcance, the difference in survival for patients
with PRA[80 and PRA\80 was also not signiﬁcant.
When analyzed by Breslow testing of Kaplan–Meier
survival curves (see Fig. 3), posttransplant survival for
patients with PRA[25 was worse than for patients
with PRA\25, although not signiﬁcantly so (P = 0.25).
Patients with PRA[80 also showed decreased sur-
vival compared with those with PRA\80 (P = 0.066).
Because of the limited number of patients with PRA
levels[25 and [80, there was not sufﬁcient power to
detect a clinical difference if one were to exist. Although
the survival plots in Fig. 3 look divergent, we cannot claim
that they are deﬁnitely different. In our cohort, the presence
of class I versus class II alloantibodies did not appear
signiﬁcant. Four of the 16 deaths that occurred after OHT
were due to CAV. Two of the three deaths that occurred in
the PRA[80 group were due to CAV, and the third was
due to multiorgan system failure. The other two deaths
from CAV occurred with patients with PRA\25. Six of
the deaths resulted from acute rejection: Five of these
patients had PRA\25, and one had PRA[25. Of the ﬁve
remaining deaths, two were caused by sudden cardiac
death, one by sepsis, one by noncompliance and rejection,
and one by unknown reasons.
Donor-Speciﬁc Cross-Matching
Two patients in this cohort had a positive donor-speciﬁc
cross-match by ﬂow cytometry. Both patients had pre-
transplant PRA[80 and were transplanted across a
weakly positive ﬂow cross-match as it was believed to be
the best option given their signiﬁcantly increased PRA
levels and diverse antibody proﬁles. There were no positive
cytotoxic cross-matches. The ﬁrst patient died 21 months
after transplantation from CAV and graft failure. There
were no episodes of acute rejection, and antibody-mediated
rejection was not detected on endomyocardial biopsy. The
second patient is alive and well three years after trans-
plantation at the time of publication. Antibody-mediated
rejectionwasnotedonbiopsyspecimensbeginning1 month
after transplantation; however, the patient remained
asymptomatic with no evidence of allograft dysfunction by
echocardiography or catheterization.
AMR
A total of 584 EMBs were included in this study, with a
mean of seven performed for each graft (range 1–19).
Twelve patients had documented AMR by at least one
EMB. Two of these patients had an EMB specimen posi-
tive for HR within 30 days of OHT, although neither
patient died during the study period. There was no signif-
icant difference in the incidence of AMR in sensitized
patients compared with nonsensitized patients. Thirty-three
percent of patients with PRA[80 showed AMR on at
least one biopsy specimen compared with 13% of patients
with PRA\80 (P = 0.28). Two of the 12 patients with
AMR on EMB (16.7%) died during the study period
compared with 14 of the 71 patients without AMR
(19.7%).
Fig. 2 Survival after listing for patients with PRA[80 and
PRA\80
Fig. 3 Survival after OHT for patients with PRA\25 and
PRA[25
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Transplantation outcomes of highly sensitized pediatric
patients were examined retrospectively. Patients with PRA
levels [25 and [80 to either class I or II antigens were
speciﬁcally considered both at the time of listing for OHT
and at the time of transplant. It is our hope that the data
provided in this manuscript will help providers to (1)
appropriately counsel the families of highly sensitized
pediatric OHT candidates and (2) assist in making difﬁcult
decisions regarding resource use with regard to highly
sensitized children. The study period was fairly long
(4 years) and was recent enough to include the more sen-
sitive ﬂow cytometric PRA measurements. However, these
data do not fully incorporate the potential beneﬁts of
virtual cross-matching for highly sensitized transplant
candidates because virtual cross-matching was used spo-
radically until becoming our standard protocol in 2007,
around the time it was established as an effective tool for
improving the outcomes after transplantation in highly
sensitized patients [14].
Our results indicate that pediatric patients with increased
pretransplant PRA values have a signiﬁcantly worse
prognosis at the time of listing compared with nonsensi-
tized patients when a negative donor-speciﬁc cross-match
is required before transplantation. Thus, the observed dif-
ference in survival was likely the result of both sensitiza-
tion and our management strategy. Although our institution
typically required a negative donor-speciﬁc cross-match
before transplantation, there is evidence that transplanting
across a positive cross-match leads to reasonable short-
term survival [15]. Because highly sensitized patients may
have a wide array of antigen speciﬁcities, these patients
remain at increased risk, even when virtual cross-matching
is used in place of donor-speciﬁc cross-matching. Ulti-
mately, transplanting across a positive virtual cross-match
is likely the most effective means of decreasing wait list
mortality in a highly sensitized patient population. How-
ever, the posttransplant implications of such a strategy
must be carefully considered.
Although there clearly was a decrease in posttransplant
survival for the highly sensitized patients included in our
study, our single-institution analysis was not large enough
to claim that the effect of high PRA values on posttrans-
plant survival is signiﬁcant. At listing, patients with a
pretransplant PRA\25 showed signiﬁcantly better sur-
vival than those with PRA[25 (P = 0.004). The differ-
ence between survival for patients with PRA\80 and
PRA[80 was even more pronounced (P = 0.002). Of
patients who received transplants, those with PRA[25
showed worse survival than patients with PRA\25, but
this was not a statistically signiﬁcant difference. A com-
parison of survival for transplanted pediatric patients with
PRA[80 and those with PRA\80 showed decreased
posttransplant survival for the PRA[80 patients, which
approached statistical signiﬁcance. Although the presence
or absence (and relative abundance) of donor-speciﬁc HLA
antibodies is likely the most important predictor of post-
transplant outcome, we believe that the absolute PRA value
may be indicative of overall sensitization status, with high
levels of anti-HLA antibodies potentially coinciding with
high levels of non-HLA antibodies.
Highly sensitized pediatric patients had much longer
wait times (and greater wait list mortality) compared with
nonsensitized patients. Early in the study period our stan-
dard practice was to require prospective cross-matches for
all sensitized patients, which limited the potential donor
pool and lengthened wait times for sensitized transplant
candidates due to the need for recipient sera to be available
near the donor hospital. More recently, we have used
virtual cross-match almost exclusively. However, even
without the requirement for prospective donor-speciﬁc
cross-matching, the donor pool for sensitized candidates is
necessarily decreased due to unacceptable antigens based
on pretransplant PRA. Potential wait times, with the
inherent implications for the patient’s quality of life, must
be considered based on the patient’s antibody proﬁle.
Every effort should be made to allow transplant candidates
with diverse antibody proﬁles to await transplantation as an
outpatient to maximize quality of life. The longevity of the
grafts in sensitized patients would also be expected to be
inferior given the presence of preformed antibodies.
Certainly, a long-term multi-institutional study of highly
sensitized pediatric patients is needed to help transplant
teams justify the use of OHT in this patient population.
However, the deﬁnition of a ‘‘successful’’ outcome is not
concrete. In our cohort with PRA levels[80, one could
certainly perceive a 45% graft survival at 3 years after
OHT (Fig. 4) as either ‘‘acceptable’’ or ‘‘unacceptable,’’
taking into consideration posttransplant quality of life
and resource use. In the meantime, desensitization ther-
apy for highly sensitized patients certainly seems war-
ranted given prolonged wait times and waitlist mortality,
which is not completely ameliorated with virtual cross-
matching. Although an increased incidence of AMR on
EMB for patients with increased PRA values was
detected, an increased incidence of graft failure and
mortality rates for patients with AMR was not docu-
mented in this study but was detected in an earlier and
longer-term study from our institution [2]. It is likely that
if followed-up for a longer period of time, the patients
with AMR in this study will also show increased mor-
tality compared with patients without AMR. It is also
possible that the difference in outcomes in our newer
data represents the beneﬁcial effects of more recent
desensitization protocols.
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In addition to being limited by its retrospective nature, our
study is certainly limited by the lack of standardized
desensitization protocol during the study period. An addi-
tional limitation lies in our use of PRA to assess the level
of recipient sensitization as opposed to the more commonly
used donor-speciﬁc antibody measurement. However, PRA
was the appropriate metric given the time the data was
collected. Additionally, PRA is still used by many centers.
Conclusion
Increased PRA at the time of listing for pediatric cardiac
transplantation is associated with increased mortality.
Patients with high PRA values have a greater chance of
dying on the wait list or after OHT than do patients
with moderately increased PRA values or nonsensitized
patients. Further research with large sample sizes and long-
term follow-up is needed to generate more conclusive data
regarding survival outcomes of patients with high PRA
values. We hope that this and future studies will better aid
clinicians in risk–beneﬁt analyses when developing treat-
ment plans for highly sensitized pediatric heart transplant
candidates.
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